Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management

被引:72
作者
El-Atat, F [1 ]
McFarlane, SI [1 ]
Sowers, JR [1 ]
机构
[1] Univ Missouri, Dept Internal Med, Columbia, MO 65212 USA
关键词
D O I
10.1007/s11906-004-0072-y
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Hypertension frequently coexists with diabetes mellitus, occurring twice as frequently in diabetic as in nondiabetic persons. It accounts for up to 75% of added cardiovascular disease (CVD) risk in people with diabetes, contributing significantly to the overall morbidity and mortality in this high-risk population. Patients with hypertension are two times more prone to have diabetes than are normotensive persons. Hypertension substantially increases the risk for coronary heart disease (CHID), stroke, retinopathy, and nephropathy. In patients with type 2 diabetes, hypertension usually clusters with the other components of the cardiometabolic syndrome, such as microalbuminuria, central obesity, insulin resistance, dyslipidemia, hypercoagulation, increased inflammation, and left ventricular hypertrophy (LVH). In type I diabetes, hypertension often occurs subsequent to the development of diabetic nephropathy. Hypertension in people with diabetes is characterized by volume expansion, increased salt sensitivity, isolated systolic blood pressure (BP) elevation, loss of the nocturnal dipping of BP and pulse, and increased propensity toward orthostatic hypotension and albuminuria. Among the treatment strategies tested in hypertensive diabetic persons, low-density lipoprotein (LDL)-cholesterol lowering to less than 100 mg/dL and aggressive BP control to less than 130/80 mm Hg have proven effective in CVD risk reduction. The combination of two or more drugs is usually necessary to achieve the target BP.
引用
收藏
页码:215 / 223
页数:9
相关论文
共 76 条
[51]   Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients [J].
Raji, A ;
Seely, EW ;
Bekins, SA ;
Williams, GH ;
Simonson, DC .
DIABETES CARE, 2003, 26 (01) :172-178
[52]   Quality of life and cough on anti hypertensive treatment: a randomised trial of eprosartan, enalapril and placebo [J].
Rake, EC ;
Breeze, E ;
Fletcher, AE .
JOURNAL OF HUMAN HYPERTENSION, 2001, 15 (12) :863-867
[53]   RELATIONSHIP BETWEEN BLOOD-PRESSURE, PLASMA-INSULIN AND TRIGLYCERIDE CONCENTRATION, AND INSULIN ACTION IN SPONTANEOUS HYPERTENSIVE AND WISTAR-KYOTO RATS [J].
REAVEN, GM ;
CHANG, H .
AMERICAN JOURNAL OF HYPERTENSION, 1991, 4 (01) :34-38
[54]   Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. [J].
Sacks, FM ;
Svetkey, LP ;
Vollmer, WM ;
Appel, LJ ;
Bray, GA ;
Harsha, D ;
Obarzanek, E ;
Conlin, PR ;
Miller, ER ;
Simons-Morton, DG ;
Karanja, N ;
Lin, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (01) :3-10
[55]   INSULIN HYPERSECRETION - A DISTINCTIVE FEATURE BETWEEN ESSENTIAL AND SECONDARY HYPERTENSION [J].
SECHI, LA ;
MELIS, A ;
TEDDE, R .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (11) :1261-1266
[56]  
SEMPLICINI A, 1994, AM J MED SCI, V307, pS43
[57]   Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry [J].
Shindler, DM ;
Kostis, JB ;
Yusuf, S ;
Quinones, MA ;
Pitt, B ;
Stewart, D ;
Pinkett, T ;
Ghali, JK ;
Wilson, AC .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (11) :1017-+
[58]   Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology [J].
Sowers, JR .
HYPERTENSION, 1997, 29 (03) :691-699
[59]   Antihypertensive therapy and the risk of type 2 diabetes mellitus [J].
Sowers, JR ;
Bakris, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (13) :969-970
[60]  
Sowers JR, 1999, DIABETES CARE, V22, pC14